Readystate Asset Management’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$728K Buy
+12,000
New +$700K 0.03% 439
2025
Q2
Sell
-45,000
Closed -$2.74M 650
2025
Q1
$2.74M Sell
45,000
-4,100
-8% -$239K 0.09% 277
2024
Q4
$2.78M Sell
49,100
-56,800
-54% -$3.17M 0.09% 242
2024
Q3
$5.48M Buy
+105,900
New +$4.97M 0.1% 282
2024
Q2
Sell
-219,300
Closed -$11.9M 741
2024
Q1
$11.9M Buy
219,300
+217,100
+9,868% +$11.1M 0.17% 129
2023
Q4
$113K Buy
+2,200
New +$115K ﹤0.01% 576

Other funds holding BMY

Readystate Asset Management's BMY Position: Q1 2026 in Review

Readystate Asset Management sold out of Bristol-Myers Squibb (BMY) in Q1 2026, closing a stake of 788,399 shares — an estimated $46M sold.

Readystate Asset Management first reported a position in BMY in Q2 2023 and held it in 3 quarters. The position peaked at $42.5M in Q4 2025. 2,518 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Readystate Asset Management reported no remaining Bristol-Myers Squibb position as of Q1 2026 after selling out during the quarter.
  • Readystate Asset Management sold 788,399 Bristol-Myers Squibb shares in Q1 2026, an estimated $46M.
  • Readystate Asset Management first reported a position in Bristol-Myers Squibb in Q2 2023 and held it in 3 quarters.
  • Readystate Asset Management's Bristol-Myers Squibb position peaked at $42.5M in Q4 2025.
  • 2,518 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Readystate Asset Management's 13F filing for Q1 2026, filed 15 May 2026.